The Hague, 15 November 2016
Eurojust, the European Union’s judicial cooperation unit, and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), have released today their first joint publication entitled New psychoactive substances in Europe. Legislation and prosecution — current challenges and solutions.
The rapid evolution of the European market for new psychoactive substances (NPS) has challenged national authorities to find suitable and efficient responses to the public health and judicial problems caused by these substances. The legal issues surrounding the control of new substances are complex, and this publication examines different control mechanisms and their implications.
This publication features:
- An analysis of Member States’ approaches to the NPS issue
- An analysis of how an EU Court of Justice ruling has left gaps in national jurisdictions which used medicine laws to regulate NPS
- Case studies from EU Member States
- A state-by-state overview of innovative laws dealing with NPS.
The report combines Eurojust’s operational experience in transnational prosecutions with the EMCDDA’s drug monitoring and analytical capacity, with the aim of resolving some of the most pressing issues faced by EU Member States in the NPS field today.
This publication is a useful tool for both policy makers and practitioners looking for solutions to the NPS problem. It responds to specific needs expressed by the Member States’ authorities participating in the European Multidisciplinary Platform Against Criminal Threats (EMPACT) on Synthetic Drugs.
You can find the publication here (Eurojust website link) and here (EMCDDA website link).